GB2598922A — Use of cannabinoids in the treatment of epilepsy

USPTO Abstract

Cannabidiol (CBD) for use in the treatment of seizures, comprising CBD with a purity of at least 95% (w/v). The CBD is administered at a starting dose of 5 mg/kg/day and within one week of administering the starting dose the dose is increased by increments of about 1-5 mg/kg. The starting dose can be increased 4, 5, or 6 days after administering the starting dose. The starting dose can be increased by about 5 mg/kg/day. The starting dose can be increased to about 10, 12, 14, 15, 16, 18, 20, or 25 mg/kg/day. The CBD can be used for treating seizures in a patient which has Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex (TSC), Doose syndrome, Aicardi syndrome, myoclonic absence epilepsy, febrile infection related epilepsy syndrome (FIRES), Sturge Weber, CDKL5 or Dup15. The seizures can be convulsive, atonic, tonic, tonic-clonic, myoclonic, or absence seizures. The seizures can be treatment resistant. The dose can be increased in weekly increments of about 5 mg/kg/day. The dose can be increased to a maximum of about 20 or 25 mg/kg/day.